Concentra Group Holdings Parent, Inc.

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, LH has a market cap of 22.7B. Regarding current trading prices, CON is priced at $22.43, while LH trades at $269.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas LH's P/E ratio is 26.14. In terms of profitability, CON's ROE is +0.47%, compared to LH's ROE of +0.10%. Regarding short-term risk, CON is less volatile compared to LH. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check LH's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, HIMS has a market cap of 4.9B. Regarding current trading prices, CON is priced at $22.43, while HIMS trades at $24.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas HIMS's P/E ratio is 43.46. In terms of profitability, CON's ROE is +0.47%, compared to HIMS's ROE of +0.23%. Regarding short-term risk, CON is less volatile compared to HIMS. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check HIMS's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, NVST has a market cap of 4.4B. Regarding current trading prices, CON is priced at $22.43, while NVST trades at $26.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas NVST's P/E ratio is 95.43. In terms of profitability, CON's ROE is +0.47%, compared to NVST's ROE of +0.02%. Regarding short-term risk, CON is less volatile compared to NVST. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check NVST's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, BBNX has a market cap of 483.8M. Regarding current trading prices, CON is priced at $22.43, while BBNX trades at $10.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas BBNX's P/E ratio is -6.02. In terms of profitability, CON's ROE is +0.47%, compared to BBNX's ROE of -0.24%. Regarding short-term risk, CON is less volatile compared to BBNX. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check BBNX's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, CV has a market cap of 238.9M. Regarding current trading prices, CON is priced at $22.43, while CV trades at $5.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas CV's P/E ratio is -10.62. In terms of profitability, CON's ROE is +0.47%, compared to CV's ROE of +0.49%. Regarding short-term risk, CON is less volatile compared to CV. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check CV's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, NAKA has a market cap of 97M. Regarding current trading prices, CON is priced at $22.43, while NAKA trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas NAKA's P/E ratio is -0.18. In terms of profitability, CON's ROE is +0.47%, compared to NAKA's ROE of -0.74%. Regarding short-term risk, CON is less volatile compared to NAKA. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check NAKA's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, CON is priced at $22.43, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas KDLY's P/E ratio is -15.48. In terms of profitability, CON's ROE is +0.47%, compared to KDLY's ROE of -0.74%. Regarding short-term risk, CON is less volatile compared to KDLY. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check KDLY's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, CON is priced at $22.43, while NEUE trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas NEUE's P/E ratio is -0.38. In terms of profitability, CON's ROE is +0.47%, compared to NEUE's ROE of +0.22%. Regarding short-term risk, CON is less volatile compared to NEUE. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check NEUE's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, PARK has a market cap of 36.2M. Regarding current trading prices, CON is priced at $22.43, while PARK trades at $18.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas PARK's P/E ratio is -103.33. In terms of profitability, CON's ROE is +0.47%, compared to PARK's ROE of -0.07%. Regarding short-term risk, CON is less volatile compared to PARK. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check PARK's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, BRK has a market cap of 11.6M. Regarding current trading prices, CON is priced at $22.43, while BRK trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas BRK's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to BRK's ROE of N/A. Regarding short-term risk, CON is less volatile compared to BRK. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check BRK's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, PFSA has a market cap of 497.3K. Regarding current trading prices, CON is priced at $22.43, while PFSA trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas PFSA's P/E ratio is -0.02. In terms of profitability, CON's ROE is +0.47%, compared to PFSA's ROE of +0.90%. Regarding short-term risk, CON is less volatile compared to PFSA. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check PFSA's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, SIRO has a market cap of 0. Regarding current trading prices, CON is priced at $22.43, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas SIRO's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, CON is less volatile compared to SIRO. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check SIRO's competition here

CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CON stands at 2.9B. In comparison, MEDC has a market cap of 0. Regarding current trading prices, CON is priced at $22.43, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CON currently has a P/E ratio of 17.37, whereas MEDC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to MEDC's ROE of N/A. Regarding short-term risk, CON is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check MEDC's competition here